Recent studies have put this AR heterogeneity in the context of tumor response to ADT/ARPIs and other therapies—although the AR+ PCa responds to enzalutamide, AR−/lo PCa and CRPC are inherently resistant to ARPIs [7, 8, 10, 11, 13]. The gene discussed is AR; the disease is posterior cortical atrophy.